Please assess the completion status of the following clinical trial:

Trial Title: Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with a diagnosis of idiopathic PD.~* Age between 30 and 75, inclusive. -Hoehn \& Yahr Stage 1.5 - 4.0 in the practically defined medication OFF. -~* History \> 2 months of excessive daytime sleepiness confirmed at baseline/screening by an Epworth Sleepiness Scale score of \> 10.~* History \> 2 months of nocturnal sleep disturbances consisting of insomnia, fragmented sleep and/or non-restorative sleep.~* Folstein Mini-Mental State Exam score of \> 24.~* Birth control for sexually active women of childbearing potential (e.g. abstinence, hormonal contraception, barrier method, intrauterine device).~* Evidence of a personally signed and dated informed consent form document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial.~* Subjects who are willing and able to comply with scheduled visits, treatment plan, and other study procedures.~* Stable dose of medications, defined as no change in dose or regimen of medications for at least 3 months prior to Screen Visit.~Exclusion Criteria:~* Known idiopathic sleep pathology: sleep apnea and narcolepsy.~* Serious co-morbid disease --Atypical parkinsonism (e.g., Parkinson plus syndrome, secondary Parkinson's syndrome). --Significant neurological symptoms not accounted for by PD. --Significant psychiatric symptoms or dementia.~* Sexually active women of childbearing potential without adequate form of birth control.~* Pregnancy or lactation.~* Mini-mental status examination of \< 25.~* Participation in another clinical trial of another investigational agent or device within the previous 60 days.~* Current abuse of alcohol or drugs.~* Active or prior malignancy other than cutaneous basal cell carcinoma or in situ carcinoma of the uterine cervix.~* Known hypersensitivity to sodium oxybate or other constituents of the product.~* Any medical conditions that are contraindications to the use of sodium oxybate or significant hepatic impairment.~* Patients being treated with sedative hypnotic agents or other central nervous system (CNS) depressants.~* Subjects taking warfarin.~* Patients with succinic semialdehyde dehydrogenase deficiency.~* Subjects who, in the opinion of the investigator, are not able to comply with the requirements of the study.~* Any other condition that, in the investigator's opinion, would cause a significant hazard to the subject.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Xyrem in Parkinson disease (Type: EXPERIMENTAL): sodium oxybate 4.5 to 9.0 gms per night

Based on this trial design, predict the completion outcome and termination type (if applicable).